Printer Friendly

Evox Therapeutics awarded key exosome patents in the US and Europe.

M2 EQUITYBITES-August 7, 2019-Evox Therapeutics awarded key exosome patents in the US and Europe

(C)2019 M2 COMMUNICATIONS http://www.m2.com

Biotechnology company Evox Therapeutics Ltd Wednesday received three key patents from the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) covering its exosome therapeutics pipeline in the US and Europe.

These three new grants are from one of several foundational patent families held by the company and further reinforce its leading position within exosome-mediated RNA therapeutics and targeted exosome drug delivery.

The company's two new US patents, which has been assigned the numbers 10,329,561 and 10,233,445, provide coverage for pharmaceutical compositions comprising exosomes containing exogenous genetic material, such as RNAi agents and antisense oligonucleotides, and targeting of exosomes to tissues of interest, respectively.

In conjunction, the company's newly granted European patent, which has been assigned the No 2419144, provides coverage for loading of exogenous genetic material into exosomes as well as targeted exosome-mediated delivery to tissues and organs of interest.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Aug 7, 2019
Words:182
Previous Article:Innophos Holdings Inc announces USD0.48 per share dividend for quarter.
Next Article:Details of Triumph Tiger revealed.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters